Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study
| dc.rights.license | open | en_US |
| dc.contributor.author | LLORCA, P. M. | |
| dc.contributor.author | BOBES, J. | |
| dc.contributor.author | FLEISCHHACKER, W. W. | |
| dc.contributor.author | HERES, S. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOORE, Nicholas | |
| dc.contributor.author | BENT-ENNAKHIL, N. | |
| dc.contributor.author | SAPIN, C. | |
| dc.contributor.author | LOZE, J. Y. | |
| dc.contributor.author | NYLANDER, A. G. | |
| dc.contributor.author | PATEL, M. X. | |
| dc.date.accessioned | 2020-11-30T12:56:19Z | |
| dc.date.available | 2020-11-30T12:56:19Z | |
| dc.date.issued | 2018-08 | |
| dc.identifier.issn | 1778-3585 (Electronic) 0924-9338 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/21262 | |
| dc.description.abstractEn | BACKGROUND: The Antipsychotic Long-acTing injection in schizOphrenia (ALTO) study was a non-interventional study across several European countries examining prescription of long-acting injectable (LAI) antipsychotics to identify sociodemographic and clinical characteristics of patients receiving and physicians prescribing LAIs. ALTO was also the first large-scale study in Europe to report on the use of both first- or second-generation antipsychotic (FGA- or SGA-) LAIs. METHODS: Patients with schizophrenia receiving a FGA- or SGA-LAI were enrolled between June 2013 and July 2014 and categorized as incident or prevalent users. Assessments included measures of disease severity, functioning, insight, well-being, attitudes towards antipsychotics, and quality of life. RESULTS: For the 572 patients, disease severity was generally mild-to-moderate and the majority were unemployed and/or socially withdrawn. 331/572 were prevalent LAI antipsychotic users; of whom 209 were prescribed FGA-LAI. Paliperidone was the most commonly prescribed SGA-LAI (56% of incident users, 21% of prevalent users). 337/572 (58.9%) were considered at risk of non-adherence. Prevalent LAI users had a tendency towards better insight levels (PANSS G12 item). Incident FGA-LAI users had more severe disease, poorer global functioning, lower quality of life, higher rates of non-adherence, and were more likely to have physician-reported lack of insight. CONCLUSIONS: These results indicate a lower pattern of FGA-LAI usage, reserved by prescribers for seemingly more difficult-to-treat patients and those least likely to adhere to oral medication. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | PharmacoEpi-Drugs | |
| dc.title.en | Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study | |
| dc.title.alternative | Eur Psychiatry | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.eurpsy.2018.04.004 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 29734130 | en_US |
| bordeaux.journal | European psychiatry | en_US |
| bordeaux.page | 85-94 | en_US |
| bordeaux.volume | 52 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20psychiatry&rft.date=2018-08&rft.volume=52&rft.spage=85-94&rft.epage=85-94&rft.eissn=1778-3585%20(Electronic)%200924-9338%20(Linking)&rft.issn=1778-3585%20(Electronic)%200924-9338%20(Linking)&rft.au=LLORCA,%20P.%20M.&BOBES,%20J.&FLEISCHHACKER,%20W.%20W.&HERES,%20S.&MOORE,%20Nicholas&rft.genre=article |
